4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one | 1123514-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one
• 英文别名: 4-[4-[[5-[4-(Difluoromethoxy)phenyl]pyrimidin-2-yl]amino]benzoyl]-1-methylpiperazin-2-one
• CAS: 1123514-43-1
• 化学式: C₂₃H₂₁F₂N₅O₃
• 分子量: 453.448
• InChiKey: JESHSULZUYYILQ-UHFFFAOYSA-N

物化性质

• 沸点：
  700.8±70.0 °C(predicted)
• 密度：
  1.353±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoic acid 、 1-甲基哌嗪-2-酮 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-(4-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-ylamino)benzoyl)-1-methylpiperazin-2-one
  参考文献：
  名称：

  [EN] 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  [FR] COMPOSÉS ET COMPOSITIONS DE 5- (4- (HALOALKOXY) PHÉNYL) PYRIMIDINE-2-AMINE UTILISÉS COMME INHIBITEURS DE KINASES

  摘要：

  该发明提供了式（1）的化合物及其制药组合物，可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或调节的激酶活性相关的疾病的方法。在某些实施方式中，该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor、b-raf激酶的疾病或紊乱的方法。

  公开号：

  WO2009026276A1

文献信息

• PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2185540A1

  公开（公告）日：2010-05-19
• 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP2190825A1

  公开（公告）日：2010-06-02
• US8293757B2
  申请人：——

  公开号：US8293757B2

  公开（公告）日：2012-10-23
• [EN] PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE PYRROLIDINE ARYLE-ÉTHER UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009019163A1

  公开（公告）日：2009-02-12

  The invention relates to a compound of general formula (I) wherein Ar1 is aryl or a five or six membered heteroaryl; Ar2 is aryl or a five or six membered heteroaryl; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, -(CH2)qR, cyano, amino, mono or di-lower alkyl amino, NHC(O)-lower alkyl, cycloalkyl or is or a five membered heteroaryl, optionally substituted by lower alkyl; wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl; R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; R3 is hydrogen or lower alkyl or CH2OH; R4 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; q is 1 or 2; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
• [EN] 5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE 5- (4- (HALOALKOXY) PHÉNYL) PYRIMIDINE-2-AMINE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：IRM LLC

  公开号：WO2009026276A1

  公开（公告）日：2009-02-26

  The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.

  该发明提供了式（1）的化合物及其制药组合物，可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或调节的激酶活性相关的疾病的方法。在某些实施方式中，该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、AbI、BCR-AbI、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-rapor、b-raf激酶的疾病或紊乱的方法。